Porton Pharma Solutions (SZSE:300363) LT-Debt-to-Total-Asset : 0.19 (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Porton Pharma Solutions LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Porton Pharma Solutions's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.19.

Porton Pharma Solutions's long-term debt to total assets ratio increased from Jun. 2023 (0.11) to Jun. 2024 (0.19). It may suggest that Porton Pharma Solutions is progressively becoming more dependent on debt to grow their business.

Porton Pharma Solutions LT-Debt-to-Total-Asset Historical Data

The historical data trend for Porton Pharma Solutions's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Porton Pharma Solutions LT-Debt-to-Total-Asset Chart

Porton Pharma Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.04

0.05

0.18

Porton Pharma Solutions Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.12	0.18	0.18	0.19

Porton Pharma Solutions LT-Debt-to-Total-Asset Calculation

Porton Pharma Solutions's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1691.724	/	9384.029
	=	0.18

Porton Pharma Solutions's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	1676.148	/	8875.511
	=	0.19

Porton Pharma Solutions (SZSE:300363) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Porton Pharma Solutions LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Porton Pharma Solutions's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Porton Pharma Solutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Porton Pharma Solutions Ltd (SZSE:300363) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

Fangzheng Avenue, Porton New Drug Outsourcing Service and R&D Center, Shuitu, Beibei District, Chongqing, CHN, 400714

Website

http://www.porton.cn

Porton Pharma Solutions Ltd is a China-based external manufacturing supplier of custom drug intermediates and Active Pharmaceutical Ingredients (APIs) to pharmaceutical companies. It is engaged in the process development activities and pilot-scale and commercial-scale manufacturing activities.

Executives

Wang Zhong Neng	Executives
Yu Yong Mei	Executives
Sun Min	Executives
Ji Yao Hui	Executives
Ju Nian Feng	Directors, executives
Tan Jun	Supervisors
Xu Ai Wu	Directors, executives
Guo Yong Qing	Independent director
	Director
	Director
Ceng Hui	Supervisors
Chen Bei	Executives

Porton Pharma Solutions Headlines

No Headlines